Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2009-02-28
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Revival Soy on Fibromyalgia Pain
NCT00279942
The Effect of Probiotic and Prebiotic Use on Fibromyalgia Syndrome
NCT04607278
Pain, Sleep and Gut Microbiota
NCT05494983
Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia
NCT01469936
The Impact of Omega-3 Fatty Acid Supplements on Fibromyalgia Symptoms
NCT01352013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
24 healthy volunteers consuming L.farciminis during three weeks
Lactobacillus farciminis
1 capsule per day. Each capsule containing 4\*109 CFU
2
24 healthy volunteers consuming placebo during three weeks
Placebo
1 capsule per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactobacillus farciminis
1 capsule per day. Each capsule containing 4\*109 CFU
Placebo
1 capsule per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lallemand SAS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
LALLEMAND SAS
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claude DUBRAY, Professor
Role: PRINCIPAL_INVESTIGATOR
CPC/CIC-INSERM 501
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cpc / Cic-Inserm 501
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-A01380-55
Identifier Type: -
Identifier Source: secondary_id
HN 08-17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.